Archives: Agenda

• How to ensure that Clinical Supplies comply with Good Clinical Practices (GCP) and with relevant regulations and standards.
• The role of Quality Management in the Supply Chain
• The role of Clinical QA in Inventory Oversight
• The importance of Documentation for traceability.

• Understanding the most common pitfalls in clinical trial planning
• How supply chain mismanagement affects study timelines and budgets
• Strategies to mitigate risks and avoid costly delays
• Lessons learned from real-world case studies and best practices for proactive study planning

• Conveying clear expectations to ensure smooth supply chain functions
• Maintaining strong communication throughout supply chain timelines to reduce the impact of roadblocks
• Ensuring efficiency through improved communication and collaboration

• Understanding geopolitical landscapes to overcome challenges and increase efficiency
• Investigating regulatory changes and evaluating the impact on clinical supply chains
• Learning how to implement strategies to decrease supply chain disruption

• Assessing current challenges when comparator sourcing
• Strategies to identify and secure a reliable vendor
• Assessing regulation to minimize delays in study startu

This forward-looking session explores how cybersecurity in financial services will evolve over the next 12–18 months. Drawing on GlobalData’s latest research, it will examine: 

• The adoption and security implications of emerging technologies – including cloud, AI, 5G, IoT, and quantum computing.
• How evolving business models and ecosystems in banking and financial services are reshaping cyber risk.
• The balance between innovation, risk, and operational resilience in an increasingly complex digital environment.

• Effective communication with target patients/families/care professionals and RETAINING them
• How inclusion of AI looks like in this communication, trust building, meeting needs and retaining engagement, from:
• Care researchers’ perspective
• Care Professionals’ perspective, and most importantly,
• Caregivers’ perspective (lived experience and real-world-evidence) in the context of “rare diseases”